Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Senti Biosciences
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
Ohio State University Comprehensive Cancer Center
Montefiore Medical Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Children's Oncology Group
Foghorn Therapeutics Inc.
M.D. Anderson Cancer Center
University of Florida
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Medical College of Wisconsin
National Cancer Institute (NCI)
Northwestern University
Nkarta, Inc.
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Ascentage Pharma Group Inc.
First Affiliated Hospital of Zhejiang University
IRCCS San Raffaele
Canadian Cancer Trials Group
University of Washington
Rush University Medical Center
Children's Oncology Group
University of Washington
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Duke University
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Bio-Path Holdings, Inc.